GPR119 is a GPCR that is predominately expressed in pancreatic beta cells and enteroendocrine cells in the GI tract in humans. Phospholipids and fatty acid amines are possible endogenous ligands, and oleylethanolamide is one of the more potent ligands known. Agonists of GPR119 elevate cyclic AMP levels in cell models which can potentiate glucose-stimulated insulin secretion. In mice, it has been showed that a GPR119 agonist stimulated the release of both GLP-1 and GIP in wildtype, but not GPR119-deficient animals. GPR119 agonists also improve glycaemic control for mice in vivo, and GLP-1 administration reduces food intake and results in weight loss in humans. Taken together, these data suggest that GPR119 could be an important target for therapeutic management of diabetes and obesity in humans.